Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
How to treat a previously treated CLL patient
Side-effect of idelalisib and its use in chronic lymphocytic leukemia
Information is key: why patients need to be empowered to learn about their disease
Next steps for advancing the molecular stratification of CLL